Carcinoma, Hepatocellular
Showing NaN - NaN of 18
Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)
Recruiting
- Carcinoma, Hepatocellular
- Relatlimab
- +3 more
-
Los Angeles, California
- +62 more
Feb 1, 2023
Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer Trial in Worldwide (RO7119929, Tocilizumab)
Completed
- Carcinoma, Hepatocellular
- +3 more
-
Duarte, California
- +9 more
Jan 27, 2023
Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab)
Active, not recruiting
- Carcinoma, Hepatocellular
-
Los Angeles, California
- +138 more
Aug 22, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab, Sorafenib)
Active, not recruiting
- Carcinoma, Hepatocellular
- Atezolizumab
- +2 more
-
Phoenix, Arizona
- +118 more
Jun 14, 2022
Carcinoma, Hepatocellular Trial in Hong Kong (embolization)
Recruiting
- Carcinoma, Hepatocellular
- embolization
-
Hong Kong, Hong KongDepartment of Imaging and Interventional Radiology, Prince of Wa
Mar 10, 2022
Carcinoma, Hepatocellular Trial in Hong Kong (Ablative chemoembolization (ACE))
Recruiting
- Carcinoma, Hepatocellular
- Ablative chemoembolization (ACE)
-
Hong Kong, Hong KongDepartment of Imaging and Interventional Radiology, Prince of Wa
Mar 10, 2022
Carcinoma, Hepatocellular Trial in Worldwide (biological, drug, other)
Active, not recruiting
- Carcinoma, Hepatocellular
- pembrolizumab
- +2 more
-
Hefei, Anhui, China
- +40 more
Mar 3, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766), Sorafenib (BAY43-9006))
Completed
- Carcinoma, Hepatocellular
- Refametinib (BAY86-9766)
- Sorafenib (BAY43-9006)
-
Louisville, Kentucky
- +78 more
Apr 6, 2021
Carcinoma, Hepatocellular, Secondary Trial in Hong Kong (Sorafenib, Capecitabine, Oxaliplatin)
Completed
- Carcinoma, Hepatocellular
- Secondary
- Sorafenib
- +2 more
-
Hong Kong, Hong KongQueen Mary Hospital
Apr 9, 2020
Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo)
Completed
- Carcinoma, Hepatocellular
- Sorafenib (Nexavar, BAY43-9006)
- +2 more
-
San Francisco, California
- +126 more
May 16, 2019
Carcinoma, Hepatocellular Trial in Worldwide (Nexavar (Sorafenib, BAY43-9006), Placebo)
Completed
- Carcinoma, Hepatocellular
- Nexavar (Sorafenib, BAY43-9006)
- Placebo
-
Birmingham, Alabama
- +198 more
Jul 11, 2018
Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin, Doxorubicin/Placebo)
Completed
- Carcinoma, Hepatocellular
- Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- Doxorubicin/Placebo
-
Birmingham, Alabama
- +27 more
Oct 24, 2014
Carcinoma, Hepatocellular Trial in Worldwide (BAY86-9766 MEK Inhibitor + Sorafenib)
Completed
- Carcinoma, Hepatocellular
- BAY86-9766 MEK Inhibitor + Sorafenib
-
Shatin, New Territories, Hong Kong
- +14 more
Sep 5, 2013
Carcinoma, Hepatocellular Trial in Hong Kong (Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Pegylated
Unknown status
- Carcinoma, Hepatocellular
- Transcatheter Arterial Chemoembolization (TACE)
- Transcatheter Arterial Pegylated Interferon Embolization (TAIE)
-
Hong Kong, ChinaQueen Mary Hospital
Jul 6, 2010
Carcinoma, Hepatocellular, Liver Tumors Trial in Hong Kong, Singapore, Taiwan (Photodynamic therapy, Talaporfin Sodium)
Completed
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Photodynamic therapy
- Talaporfin Sodium
-
Hong Kong, Hong Kong
- +8 more
Dec 5, 2007